Recursion Pharmaceuticals, Inc. Class A RXRX 深 滬
已收盤 05-15 16:00:00 美东时间
2.93
-0.110
-3.62%
華盛通- 最 高3.05
- 今 開3.00
- 成交量 1741.80万股
- 最 低 2.92
- 昨 收 3.04
- 總市值 15.53亿
- 52周最高 7.18
- 市盈率 靜 --
- 換手率 3.29%
- 52周最低 2.80
- 委 比 -23.88%
- 總股本 5.30亿
- 歷史最高 42.81
- 量 比 1.23
- 振 幅 4.28%
- 歷史最低 2.80
- 每 手 1
- 風險率 0.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Morgan Stanley Maintains Equal-Weight on Recursion Pharmaceuticals, Raises Price Target to $5.5
Morgan Stanley analyst Vikram Purohit maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Equal-Weight and raises the price target from $5 to $5.5.
05-15 01:23
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
财报速睇 | Recursion Pharmaceuticals, Inc. Class A 2026财年Q1营收0.06亿美元，同比下降56.1%；归母净利润亏损1.18亿美元，同比亏损缩窄42.0%
华盛资讯5月6日讯，Recursion Pharmaceuticals, Inc. Class A公布2026财年Q1业绩，公司Q1营收0.06亿美元，同比下降56.1%，归母净利润亏损1.18亿美元，同比亏损缩窄42.0%。
05-06 20:37
财报速睇 | Recursion Pharmaceuticals, Inc. Class A 2026财年Q1营收0.06亿美元，同比下降56.1%；归母净利润亏损1.18亿美元，同比亏损缩窄42.0%
华盛资讯5月6日讯，Recursion Pharmaceuticals, Inc. Class A公布2026财年Q1业绩，公司Q1营收0.06亿美元，同比下降56.1%，归母净利润亏损1.18亿美元，同比亏损缩窄42.0%。
05-06 19:20
Recursion Pharmaceuticals misses Q1 operating revenue estimates, net loss narrows
Recursion Pharmaceuticals misses Q1 operating revenue estimates, net loss narrows Overview US drug discovery firm's Q1 operating revenue missed analyst expectations Q1 net loss narrowed, helped by lower R&D and admin costs Company reiterates 2026 operational cash burn guidance, expects cash runway i
05-06 18:43
Recursion Pharmaceuticals Q1 EPS $(0.22) Beats $(0.27) Estimate, Sales $6.472M Miss $15.777M Estimate
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.27) by 18.52 percent. This is a 56 percent increase over losses of $(0.50) per share
05-06 18:31
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $10
JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $11 to $10.
05-01 06:42
